about
The clinical pharmacology of acamprosate.Determination of [(11)C]PBR28 binding potential in vivo: a first human TSPO blocking study.Evidence of Brain Inflammation in Patients with Human T-Lymphotropic Virus Type 1-Associated Myelopathy (HAM): A Pilot, Multimodal Imaging Study Using 11C-PBR28 PET, MR T1-Weighted, and Diffusion-Weighted Imaging.Microglial Activity in People at Ultra High Risk of Psychosis and in Schizophrenia: An [(11)C]PBR28 PET Brain Imaging Study.Neuroinflammation in treated HIV-positive individuals: A TSPO PET study.Neuropharmacology of addiction and how it informs treatment.The Imperial College Cambridge Manchester (ICCAM) platform study: An experimental medicine platform for evaluating new drugs for relapse prevention in addiction. Part A: Study description.Alcohol and Alzheimer's Disease-Does Alcohol Dependence Contribute to Beta-Amyloid Deposition, Neuroinflammation and Neurodegeneration in Alzheimer's Disease?Decreased hippocampal translocator protein (18 kDa) expression in alcohol dependence: a [11C]PBR28 PET studyA pilot study of the effectiveness of D-cycloserine during cue-exposure therapy in abstinent alcohol-dependent subjects.Using [(11)C]Ro15 4513 PET to characterise GABA-benzodiazepine receptors in opiate addiction: Similarities and differences with alcoholism.Characterisation of the contribution of the GABA-benzodiazepine α1 receptor subtype to [(11)C]Ro15-4513 PET imagesFootnotes to Kraepelin: changes in the classification of mood disorders with DSM-5.Are prescribed benzodiazepines likely to affect the availability of the 18 kDa translocator protein (TSPO) in PET studies?Determination of [11C]PBR28 binding potential in vivo: a first human TSPO blocking study.Bipolar disorder and addictions: the elephant in the room.Resting state synchrony in anxiety-related circuits of abstinent alcohol-dependent patients.Toxicity: exploring and expanding the concept.History of cigarette smoking is associated with higher limbic GABAA receptor availability.11C-PBR28 and 18F-PBR111 Detect White Matter Inflammatory Heterogeneity in Multiple Sclerosis.Central noradrenergic responsiveness to a clonidine challenge in Generalized Anxiety Disorder: a Single Photon Emission Computed Tomography study.Acute increases in synaptic GABA detectable in the living human brain: a [¹¹C]Ro15-4513 PET study.Addressing substance misuse: a missed opportunity in suicide preventionSpice and all things nasty: the challenge of synthetic cannabinoidsSpicing it up - synthetic cannabinoid receptor agonists and psychosis - a systematic reviewInvestigation into the neural correlates of emotional augmentation of clinical painMeasurement of GABA using J-difference edited1H-MRS following modulation of synaptic GABA concentration with tiagabineNoradrenergic function in generalized anxiety disorder: impact of treatment with venlafaxine on the physiological and psychological responses to clonidine challengeHeroin-induced respiratory depression and the influence of dose variation: within-subject between-session changes following dose reductionSynthetic cannabinoid use in psychiatric patients and relationship to hospitalisation: A retrospective electronic case register studyHarm reduction in opioid treatment: an established idea under threat
P50
Q27687874-7FA5DDA4-7AFB-47BD-994C-F375D828EC5BQ33729262-2169C510-3ACC-4141-B1B3-020F319B3398Q36113536-707C45D8-92C6-4129-B9EA-5470B7BCFE75Q36766806-BF67AF8D-78B6-44C9-8A69-7C099D9316C4Q36796466-06AC40A9-341A-4ECC-A4F9-1713EB21F709Q37806446-D1E55DED-73FE-4B0F-9E1F-3A1A5BC6DB68Q38977208-9D7C2787-2BF0-4AE3-82B2-59BF8E074464Q39028577-0A15467A-23AE-48BF-AB70-56CBE8C9D434Q39029440-8201EDF2-ED39-4E2F-9725-7CAB89879363Q39783270-D2FA8898-C229-4FE5-9227-5082D9D68B3CQ41330573-3F3660B8-D0B7-4979-BBF8-4112E37DF584Q42144042-DACB62F9-035E-468F-AD05-4C93DDBB2578Q42352664-E9F72D2B-4B30-49A7-B14A-0DA8B133B852Q45787444-255C1657-2ED0-4B0F-A6BB-F407B69523BAQ45982601-001CA8F4-63D4-4838-B813-E403A2F7A792Q47631258-5A9B4404-453A-4B03-B74F-DB680961A684Q47960201-ED237ADA-05A8-4A4E-90C5-BD5D28C123FDQ48179091-7E30123D-2BE3-40D7-A4A9-BCDBA02BE229Q48250500-1510F7F7-914B-4022-8467-0B57D9BC898EQ48259790-CB521C99-9F38-4DA0-BF7F-69E6D12B0538Q48892366-9FEDFF3C-7FCB-499C-B6BF-862320B85FFAQ50661371-566A0BBE-D6E6-4A2B-A46E-86816005577CQ57279505-D00C690C-D4B0-4AF2-815D-D113B1D755D9Q59768465-379A30E2-3164-413C-A56D-A586C155D0C9Q60440017-2BA1BDE1-D656-4B16-ABF4-D7EF0416AF1EQ61888046-B11F939F-F66F-4216-A2B7-4829AF64A69CQ62476968-3245D9BF-4EED-4559-9768-323D07DA2727Q62476980-E8E928D9-6A00-4F45-A122-25D64A4C359FQ89710818-933E4376-28A6-414E-BE42-69DE132F0C02Q89932671-6FCF6968-2AF5-4B42-A231-801AF66D2112Q93185968-AFC3782E-3E1C-49AC-8C48-AF7A5D698AEC
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Nicola Kalk
@en
Nicola Kalk
@es
Nicola Kalk
@nl
Nicola Kalk
@sl
Nicola KalkNicola Jayne Kalk
@fr
type
label
Nicola Kalk
@en
Nicola Kalk
@es
Nicola Kalk
@nl
Nicola Kalk
@sl
Nicola KalkNicola Jayne Kalk
@fr
altLabel
Nicola Jayne Kalk
@en
Nicola Jayne Kalk
@fr
prefLabel
Nicola Kalk
@en
Nicola Kalk
@es
Nicola Kalk
@nl
Nicola Kalk
@sl
Nicola KalkNicola Jayne Kalk
@fr
P106
P1153
23467026500
P21
P31
P496
0000-0002-3820-9243